These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 11571337

  • 1. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD, Quinless JR, Jotkowitz A, Beaton P, Neutralizing Antibody Study Group.
    Neurology; 2001 Sep 25; 57(6):1080-4. PubMed ID: 11571337
    [Abstract] [Full Text] [Related]

  • 2. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM, Rudick RA, Munschauer FE, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.
    Mult Scler; 2005 Aug 25; 11(4):409-19. PubMed ID: 16042223
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT.
    Neurology; 2003 Feb 25; 60(4):634-9. PubMed ID: 12601105
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE, Cookfair DL, Simon JH, Jacobs LD.
    Neurology; 1998 May 25; 50(5):1266-72. PubMed ID: 9595973
    [Abstract] [Full Text] [Related]

  • 9. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA, Dhib-Jalbut SS.
    Neurology; 1998 Dec 25; 51(6):1698-702. PubMed ID: 9855525
    [Abstract] [Full Text] [Related]

  • 10. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC.
    Neurology; 2007 Mar 27; 68(13):977-84. PubMed ID: 17389300
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
    Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G.
    J Neurol; 2007 May 27; 254(5):597-604. PubMed ID: 17420930
    [Abstract] [Full Text] [Related]

  • 13. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
    Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T.
    Neurology; 1999 Apr 12; 52(6):1239-43. PubMed ID: 10214750
    [Abstract] [Full Text] [Related]

  • 14. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R.
    Immunopharmacology; 2000 Jul 20; 48(2):95-100. PubMed ID: 10936507
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
    Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S.
    Clin Ther; 2004 Apr 20; 26(4):511-21. PubMed ID: 15189748
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS.
    J Manag Care Pharm; 2004 Jun 20; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [Abstract] [Full Text] [Related]

  • 19. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators.
    Neurology; 2009 Nov 03; 73(18):1493-500. PubMed ID: 19884577
    [Abstract] [Full Text] [Related]

  • 20. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F.
    Mult Scler; 2012 May 03; 18(5):610-5. PubMed ID: 22013146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.